Patents for A61P 35 - Antineoplastic agents (221,099)
07/2007
07/17/2007US7244718 Derivatives of water insoluble drugs which exhibit good activity and water solubility; producing an anesthetic effect in a dog
07/17/2007US7244711 Mixtures of enzyme inhibitors and free radical scavengers selected from phenolic compounds, phenothiazines and diphenylamines, used for prophylaxis of rheumatic diseases, pancreatitis, multiple sclerosis or gastrointestinal disorders
07/17/2007US7244604 HDAC9 polypeptides and polynucleotides and uses thereof
07/17/2007US7244449 Liposome-entrapped topoisomerase inhibitors
07/17/2007US7244448 Providing liposome having free active agent and precipitated active agent encapsulated therein; varying amount of active agent that is precipitated in liposome for modulation plasma circulation half-life of active agent
07/17/2007US7244429 Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
07/17/2007CA2388639C Inhibitors of .alpha.l.beta.2 mediated cell adhesion
07/17/2007CA2348767C Method for producing an antitumoral agent and antitumoral agent thus obtained
07/17/2007CA2321369C Dosing regimens for lasofoxifene
07/17/2007CA2305655C Self-deleting vectors for cancer therapy
07/17/2007CA2283198C Butyrate prodrugs derived from lactic acid
07/17/2007CA2172506C Mycophenolate mofetil and mycophenolic acid high dose oral suspensions
07/17/2007CA2160161C Use of derivatives of 2,4-bisubstituted phenols as 5-lipoxigenase inhibitors
07/12/2007WO2007079214A2 Prokineticin 2 receptor antagonists
07/12/2007WO2007079169A2 Treatment for acute myeloid leukemia
07/12/2007WO2007079146A1 Treatment for non-hodgkin's lymphoma
07/12/2007WO2007079086A1 Pyrazoloalkyl substituted imidazo ring compounds and methods
07/12/2007WO2007078007A1 Carbon nanohorn structure, composition capable of controlling the release of organic substance included therein, and method for the controlled release
07/12/2007WO2007077949A1 Heterocyclic janus kinase 3 inhibitors
07/12/2007WO2007077934A1 Anti-periostin antibody and pharmaceutical composition for preventing or treating periostin-related disease containing the same
07/12/2007WO2007077861A1 NF-κB INHIBITOR
07/12/2007WO2007077606A1 Efficacy enhancer for alternative therapeutic agent and anticancer preparation making use of the same
07/12/2007WO2007077528A1 Irradiated compositions and treatment of cancers with radiation in combination with taurolidine and/or taurultam
07/12/2007WO2007077435A1 Pharmaceutical compounds
07/12/2007WO2007077309A1 Combination comprising combretastatin and anticancer agents
07/12/2007WO2007077203A2 Triterpenequinone and triterpenephenol derivatives and their application for the treatment of tumors and parasitic diseases
07/12/2007WO2007077173A1 Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
07/12/2007WO2007076950A1 Anti-cd19 antibodies with reduced immunogenicity
07/12/2007WO2007076927A1 Anti-il-6 antibodies preventing the binding of il-6 complexed with il-6ralpha to gp130
07/12/2007WO2007076923A1 Combination therapy using anti-egfr and anti-her2 antibodies
07/12/2007WO2007076704A1 Aryl dihydro-naphthalene compounds, their preparation and their use as akt inhibitor for the prevention and treatment of cancer
07/12/2007WO2007064345A9 Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use
07/12/2007WO2007062107A3 Immunostimulatory oligoribonucleotides
07/12/2007WO2007062073A3 Models of metastatic tumors
07/12/2007WO2007059257A8 N4-phenyl-quinaz0line-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
07/12/2007WO2007058992A3 Mutations and polymorphisms of hdac6
07/12/2007WO2007054719A3 Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent
07/12/2007WO2007054279A8 Cyclic-dinucleotides and its conjugates as adjuvants and their uses in pharmaceutical compositions
07/12/2007WO2007051462A3 Use of tetraorganosilicon compounds
07/12/2007WO2007048070A3 Pyrrolo-pyridine derivatives for the treatment of cancer diseases
07/12/2007WO2007044616A3 Optimized anti-cd30 antibodies
07/12/2007WO2007041294A3 Methods for sensitizing cancer cells to inhibitors
07/12/2007WO2007034279A3 C3a antagonists and pharmaceutical compositions thereof
07/12/2007WO2007029078A3 Succinimide and glutarimide derivatives as adrenergic receptor antagonists
07/12/2007WO2007026251A3 Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma
07/12/2007WO2007021937A3 Unsaturated heterocyclic derivatives
07/12/2007WO2007005670A3 Natural and synthetic sulfoxide, selenone and selenoxide analogs and polymer conjugated forms thereof for the modulation of angiogenesis
07/12/2007WO2006135783A3 Compositions and methods for modulating angiogenesis
07/12/2007WO2006111971A3 Photodynamic therapy using chemiluminescence and a ligand-photosensitiser conjugate
07/12/2007WO2003077723A3 Methods and devices for detection and therapy of atheromatous plaque
07/12/2007US20070161712 Genes encoding epsilon lycopene cyclase and method for producing bicyclic epsilon carotene
07/12/2007US20070161707 Pharmaceutical uses for alpha2delta ligands
07/12/2007US20070161706 Pharmaceutical uses for alpha2delta ligands
07/12/2007US20070161692 Conformationally restricted polyamine analogs as disease therapies
07/12/2007US20070161681 Ether derivatives useful as inhibitors of pde4 isozymes
07/12/2007US20070161671 7-Azaindoles and the use thereof as therapeutic agents
07/12/2007US20070161669 Benz-indole and benzo-quinoline derivatives as prodrugs for tumor treatment
07/12/2007US20070161666 Pyrrolo[2,3-d]pyrimidine compounds
07/12/2007US20070161635 Kinase inhibitors
07/12/2007US20070161632 Tyrosine kinase inhibitors; antiproliferative agents; antitumor agents
07/12/2007US20070161626 Substituted Indazoles, Compositions Containing The Same, And The Preparation And Use Thereof
07/12/2007US20070161602 Phosphonate compounds
07/12/2007US20070161597 A time-release formulation of a water-soluble derivative having the fatty acid moiety removed and an antiinflammatory agent; opoid resistant neuropathic pain, amputation pain or neuralgia;
07/12/2007US20070161579 Nymphaeol-A, nymphaeol-B and nymphaeol-C; microbiocide, antitumor agent, food, beverage and cosmetic preservative; antioxidant food supplement
07/12/2007US20070161564 Methods for making Apo-2 ligand using divalent metal ions
07/12/2007US20070161549 Glycosylation-deficient hepatocyte growth factor
07/12/2007US20070161080 Antibodies
07/12/2007US20070161073 Methods and products related to evaluating the quality of a polysaccharide
07/12/2007US20070161063 Identifying, monitoring, and treating women for breast precancer or cancer
07/12/2007US20070161046 Truncated aggrecanase molecules
07/12/2007US20070161021 Novel nucleic acids and polypeptides related to a guanine exchange factor of Rho GTPase
07/12/2007US20070160697 Cancer metastasis inhibitory composition
07/12/2007US20070160694 Preventives or remedies for tumor or human papillomaviral disease
07/12/2007US20070160668 Prolonged release bioadhesive therapeutic systems
07/12/2007US20070160657 Targeting and intestinal-absorption controlled liposome having sugar chain and therapeutic drug for cancer and diagnostic drug containing the liposome
07/12/2007US20070160631 Novel immunogenic lipopeptides comprising t-helper and cytotoxic t lymphocyte (ctl) epitopes
07/12/2007US20070160614 Human TIMP-1 antibodies
07/12/2007US20070160608 Treatment with anti-vegf antibodies
07/12/2007US20070160603 Antibodies Against Tumor Necrosis Factor Delta (APRIL)
07/12/2007US20070160600 Compositions and methods of monoclonal and polyclonal antibodies specific for T cell subpopulations
07/12/2007US20070160587 Allogeneic tumor therapeutic agent, a vaccine using allogeneic tumor cells for the therapeutic treatment of tumor diseases, and a method for the making of such a vaccine, and transfected human tumor cells for use as a vaccine
07/12/2007US20070160539 HPRP4s Modifiers of the p53 Pathway and Methods of Use
07/12/2007US20070160529 Radioimmunoconjugates for targeted alpha therapy
07/12/2007DE102006001213A1 Synergistische Lösung aus Ascobinsäure oder deren Derivaten und Metallionen effizienten, selektiven Abtötung pathologischer Säugerzellen Synergistic solution of Ascobinsäure or their derivatives and metal ions efficient, selective killing of pathological mammalian cells
07/12/2007CA2671322A1 Compositions and methods for treating actin-mediated medical conditions by administering an actin modulating agent
07/12/2007CA2636074A1 Combination therapy using anti-egfr and anti-her2 antibodies
07/12/2007CA2635850A1 Heterocyclic janus kinase 3 inhibitors
07/12/2007CA2635849A1 An antibody against periosin, and a pharmaceutical composition comprising it for preventing or treating a disease in which periosin is involved
07/12/2007CA2635845A1 Prokineticin 2 receptor antagonists
07/12/2007CA2635842A1 Prokineticin 1 receptor antagonists
07/12/2007CA2635623A1 Anti-cd19 antibodies with reduced immunogenicity
07/12/2007CA2635615A1 Anti-il-6 antibodies preventing the binding of il-6 complexed with il-6ralpha to gp130
07/12/2007CA2635318A1 Triterpenequinone and triterpenephenol derivatives and their application for the treatment of tumors and parasitic diseases
07/12/2007CA2635231A1 Protein kinase inhibitors
07/12/2007CA2634989A1 Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
07/12/2007CA2633222A1 Antibodies directed to her-3 and uses thereof
07/12/2007CA2631108A1 Combination comprising combretastatin and anticancer agents
07/11/2007EP1806404A1 Isolated nucleic acid molecules which encode T cell inducible factors, or interleukin-21, the proteins encoded, and uses thereof
07/11/2007EP1806365A1 Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
07/11/2007EP1806364A2 New anti-IGF-IR antibodies and their applications